Navigation Links
Experimental Vaginal Gel Doesn't Ward Off HIV

South African women using Carraguard had no decrease in infections, trial found

THURSDAY, Dec. 4 (HealthDay News) -- A microbicidal vaginal gel called Carraguard doesn't protect women from HIV infection.

That's the conclusion of a study that included more than 6,200 sexually-active, HIV-negative women at three sites in South Africa.

The women were given either Carraguard or a placebo gel and told to use one applicator of gel and a condom each time they had vaginal sex. The women, who were followed for up to two years, visited a clinic every three months to have tests for HIV infection and pregnancy, pelvic examinations, risk reduction counseling, and treatment for curable sexually transmitted diseases and vaginal infections.

The rate of HIV infection among women using Carraguard was 3.3 per 100-woman years, compared with 3.8 per 100-woman years in the placebo group. Rates of self-reported gel use were similar in both groups (96.2 percent Carraguard, 95.9 percent placebo), but applicator testing indicated that actual gel use was much lower (41.1 percent Carraguard, 43.1 percent placebo). Self-reported condom use was 64.1 percent for both groups.

The findings were published in this week's issue of The Lancet.

"This study did not show Carraguard's efficacy in prevention of male-to-female transmission of HIV, although no safety concerns were recorded. Low levels of gel use could have compromised the potential to detect a significant protective effect. Although the results from this and other completed microbicide efficacy trials have been disappointing, the search for female-controlled HIV-prevention methods must continue," wrote researchers from the Population Council in New York City and their colleagues.

Carraguard, a carrageenan-based compound, was developed by the Population Council.

In an accompanying comment, Dr. Willard Cates and Dr. Paul Feldblum, of Family Health International in North Carolina, wrote that no single method of HIV prevention will be adequate.

"Rather a combination of partly effective prevention approaches will be bundled into packages targeted to specific populations. This bundling will involve behavioral, biomedical, and structural interventions, each designed to reinforce the effect of the other. The cumulative influence of combination prevention is our hope for thwarting the spread of HIV," they said.

More information

The U.S. Centers for Disease Control and Prevention has more about HIV infection risk factors and prevention.

-- Robert Preidt

SOURCE: The Lancet, news release, Dec. 5, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
Related Image:
Experimental Vaginal Gel Doesn't Ward Off HIV
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
Breaking Medicine Technology: